Intensity Therapeutics Inc (INTS) Stock Price, Quote & News

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Industry: Biotechnology

Sector: Healthcare

Phone: 203 221 7381

Fax: 203 557 3023

Website: www.intensitytherapeutics.com

Address:

1 Enterprise Drive, Suite 430, Shelton, United States

Dannyrotorpilot Feb. 3 at 10:30 PM

$INTS

0 · Reply

Martin31278 Feb. 3 at 2:49 PM

$INTS https://x.com/IntensityInc/status/2018678361615126557?s=20

1 · Reply

Dannyrotorpilot Feb. 2 at 10:16 PM

$INTS any one here in CATX? I have some calls in it. Think that’s where my money will go if I pull out of this.

0 · Reply

IggieKooppa Feb. 2 at 8:23 PM

$INTS Ian Walters Track record... Everything and anything this dirtbag touched turned into a turd or 🦗 Look how bad and how he diluted PRTG to nothing and become crypto shell ATON. All BIOTECH IP suddenly has no value or has been transferred over and is private after they diluted investors to the ground. I hope Lewis ain't thinking he is getting away with the same corrupt play by Ian. 🔘Intensity Therapeutics (INTS) 🔘Sorrento Therapeutics (SRNE) 🔘SalvaRx Group Plc (and portfolio/subsidiaries) 🔘iOx Therapeutics (SalvaRx/Portage subsidiary) 🔘Tarus Therapeutics (’merged into Portage) 🔘Portage Biotech (PRTG → AlphaTON Capital / ATON) 🔘Enzo Biochem (ENZ) Many entities were folded into Portage (SalvaRx, Tarus) Lewis Lewis Lewis...

1 · Reply

Swerbian Feb. 2 at 6:04 PM

$INTS merck and pfizer earnings tmw. Would love to see a partnership announcement

0 · Reply

lamMBD Feb. 2 at 4:59 PM

$INTS Quiet b4 the storm! MBD

1 · Reply

Dannyrotorpilot Feb. 2 at 3:51 PM

$INTS why can’t INTS be run like $CATX. Maybe it’s management. 🤦 Come on INTS.

1 · Reply

SBEEE Jan. 30 at 7:33 PM

$INTS Here is a big buy at 1:59 pm almost 670k.

1 · Reply

IggieKooppa Jan. 30 at 7:09 PM

$INTS merck......

0 · Reply

EyeLikeTheStonk Jan. 30 at 6:56 PM

$INTS Lew better stop playing with his hobby chickens and start pushing some PR. Investors are getting bored

0 · Reply

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Dec 11, 2025, 7:47 AM EST - 7 weeks ago

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Dec 5, 2025, 7:30 AM EST - 2 months ago

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 4, 2025, 7:47 AM EST - 2 months ago

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

Nov 6, 2025, 4:02 PM EST - 3 months ago

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 1:36 PM EDT - 3 months ago

Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript

Oct 31, 2025, 8:00 AM EDT - 3 months ago

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

$Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal$

Oct 30, 2025, 7:30 AM EDT - 3 months ago

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Sep 10, 2025, 7:47 AM EDT - 5 months ago

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Sep 2, 2025, 7:47 AM EDT - 5 months ago

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:47 AM EDT - 6 months ago

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Aug 7, 2025, 4:06 PM EDT - 6 months ago

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 4, 2025, 7:47 AM EDT - 6 months ago

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Jun 30, 2025, 8:00 AM EDT - 7 months ago

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Jun 11, 2025, 11:46 PM EDT - 8 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 4:06 PM EDT - 8 months ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 11, 2025, 8:30 AM EDT - 8 months ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

May 29, 2025, 8:00 AM EDT - 8 months ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 28, 2025, 8:00 AM EDT - 8 months ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 13, 2025, 4:06 PM EDT - 9 months ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 9 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Apr 25, 2025, 8:00 AM EDT - 10 months ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Mar 13, 2025, 4:07 PM EDT - 11 months ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Jan 28, 2025, 8:00 AM EST - 1 year ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 10, 2025, 8:00 AM EST - 1 year ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Dec 12, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Nov 21, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 18, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 13, 2024, 4:06 PM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:19 PM EDT - 1 year ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

May 15, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 14, 2024, 9:38 AM EDT - 1 year ago

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

May 10, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 9, 2024, 4:08 PM EDT - 1 year ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 2, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Mar 14, 2024, 4:09 PM EDT - 2 years ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Feb 21, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Jan 3, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Dec 12, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Dec 8, 2023, 8:30 AM EST - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Dec 1, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Nov 13, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

$Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023$

Nov 2, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Sep 7, 2023, 8:01 AM EDT - 2 years ago

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Sep 5, 2023, 8:01 AM EDT - 2 years ago

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Dannyrotorpilot Feb. 3 at 10:30 PM

$INTS

0 · Reply

Martin31278 Feb. 3 at 2:49 PM

$INTS https://x.com/IntensityInc/status/2018678361615126557?s=20

1 · Reply

Dannyrotorpilot Feb. 2 at 10:16 PM

$INTS any one here in CATX? I have some calls in it. Think that’s where my money will go if I pull out of this.

0 · Reply

IggieKooppa Feb. 2 at 8:23 PM

1 · Reply

Swerbian Feb. 2 at 6:04 PM

$INTS merck and pfizer earnings tmw. Would love to see a partnership announcement

0 · Reply

lamMBD Feb. 2 at 4:59 PM

$INTS Quiet b4 the storm! MBD

1 · Reply

Dannyrotorpilot Feb. 2 at 3:51 PM

$INTS why can’t INTS be run like $CATX. Maybe it’s management. 🤦 Come on INTS.

1 · Reply

SBEEE Jan. 30 at 7:33 PM

$INTS Here is a big buy at 1:59 pm almost 670k.

1 · Reply

IggieKooppa Jan. 30 at 7:09 PM

$INTS merck......

0 · Reply

EyeLikeTheStonk Jan. 30 at 6:56 PM

$INTS Lew better stop playing with his hobby chickens and start pushing some PR. Investors are getting bored

0 · Reply

joel12365 Jan. 30 at 6:34 PM

$INTS they way i see it is yes 20 million raise could be maybe quarter dilution but getting phase 2 breast cancer pcr first patient continues trend then we have two multi billion doller companies bidding they wont want ints being expensive so expecting 15-20 patients data treated 8 already to kick start this rush also partnered trials carnt not release there data to public so the race is on if good.

0 · Reply

joel12365 Jan. 30 at 6:27 PM

$INTS for thedumbass saying people shouldnt be patient The most important point people are missing If the intent were to “dump and shell”, you would NOT invest in Phase 2/3 oncology. That is the worst possible path for that strategy: • expensive • slow • highly regulated • transparent If the goal were a shell flip: • they’d pivot to AI / platform buzz • they’d avoid controlled trials • they’d stop burning cash on clinics INTS is doing the opposite.

0 · Reply

Dannyrotorpilot Jan. 30 at 3:37 PM

$INTS @IggieKooppa if they pump this to $15.00 I can retire. But having said that, I have a timeline set on this stock. If nothing positive happens by then, I’m out will my now 6 figures worth of shares. If someone from INTS reads any of this, don’t be douche bags like this Ian Walter. I’m bullish about the product and tech, but for the life of me I don’t understand why they would put a douche on the board that screwed so many other people.

2 · Reply

IggieKooppa Jan. 30 at 2:46 PM

$INTS Ian Walter from Tarus and Portage is doing the same thing. Such potential this and that, suddenly need funding and diluted and pumped PRTG from $3 to $15. They also invested in INTS. Next thing you know… Ooopp we’re pausing the trial temporarily & need funding . A few months later they abandoned the entire biotech portion and sold the company as a shell for $4 mil to ATON (crypto). Tarus Therapeutic is a wholly owned sub again (private) and since 2020 not one thing Ian Walter has done to bring real value. So shut up with being patient. It’s the history and the people that run the biotech that are the freaking problem. And the investors behind INTS are the same people behind Portage including the Discord group. Now this 🦗🦗 need $20 mil. Jeez You can be bullish but not blind.

0 · Reply

IggieKooppa Jan. 30 at 2:35 PM

$INTS come on Lewis.. Don't be like Ian Walter.

0 · Reply

joel12365 Jan. 29 at 7:46 PM

$INTS People being impatient shouldn’t invest in anything bio tech can take a year before anything vital news were expecting merck bns partnered phase data (should be ready) or by spring summer thing need to stay quite due to laws around partnerships and funding especially the bigger the deal ints covers most tumour partnering with the biiggest to do it. silence isgood also partners have to declare when partnersip come to and end not happened i would of investedt more this month but ive got lev copper untill i buy this with profits

0 · Reply

lamMBD Jan. 29 at 5:34 PM

$INTS Just market maker crosses for the most part in my opinion. Boxing in the bid/ask while also selling to each other to make the stock appear weak!!! In my forty plus years of investing, i've seen all the games!!! MBD

0 · Reply

Pettechfl Jan. 29 at 5:13 PM

$INTS Calm down, just noise following the markets. Don’t need PR once data comes out. we saw that a couple months ago. My guess is they know they have good enough data coming before June to get over $1.

0 · Reply

EyeLikeTheStonk Jan. 29 at 4:13 PM

$INTS pushed down on 500k shares traded. I’ll buy more

0 · Reply

lamMBD Jan. 29 at 3:46 PM

$INTS This is playing out just like the MM's and shorts want it to!! Have seen this so many times and have been on this end, panick selling!! Watch what happens very soon. Those who have gotten impatient, panic selling, unfortunately going to lose out big here!!! Jmo! Everyone has to do what they have to do! MBD

0 · Reply

MoneyClaw Jan. 29 at 3:39 PM

$INTS .35 has been a solid support level. Don't let it break!

1 · Reply

IggieKooppa Jan. 29 at 3:05 PM

$INTS Hope Lewis Bender doesn't repeat Portage and Peter Molloy's dirty work. Potential this, potential that.. Next thing you know poof with nothing. Management is shit head or just stupid with PR.

1 · Reply

Market Cap	21.96M
Revenue (ttm)	0.00
Net Income (ttm)	-16.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	864,800
Avg Vol	2,076,980
Day's Range	N/A - N/A
Shares Out	60.07M
Stochastic %K	15%
Beta	3.56
Analysts	Sell
Price Target	$2.90